JPMorgan analyst Lisa Gill raised the firm’s price target on Progyny (PGNY) to $26 from $25 and keeps a Neutral rating on the shares. The company reported a good Q3 and has positive selling season trends heading into fiscal 2026, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGNY: